Sugi Predict

Sugi Predict / Compounds / SCHEMBL24685166

SCHEMBL24685166

SCHEMBL24685166

COC(=O)c1c(Br)cc(=O)n(C)c1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.39
▸ HSD17B10 Q99714 3/20 0.39
▸ TSHR P16473 3/20 0.39
▸ GLA P06280 1/20 0.39
▸ ALDH1A1 P00352 5/20 0.37
▸ KMT2A Q03164 5/20 0.36
▸ HPGD P15428 3/20 0.36
▸ CYP1A2 P05177 3/20 0.36
▸ MAPT P10636 2/20 0.36
▸ CYP2C19 P33261 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ CYP2C9 P11712 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ PPARG P37231 1/20 0.35
▸ MAPK10 P53779 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26655052 0.81 KMT2A (0.37) KDM4EHSD17B10ALDH1A1KMT2AHPGD
SCHEMBL24685188 0.81 KDM4E (0.39) KDM4EHSD17B10TSHRGLAALDH1A1
SCHEMBL24685172 0.75 KDM4E (0.35) KDM4EHSD17B10TSHRGLAALDH1A1
SCHEMBL24682466 0.73 CA12 (0.42) KDM4EHSD17B10TSHRGLAALDH1A1
SCHEMBL26033344 0.73 KDM4E (0.34) KDM4EHSD17B10TSHRGLAALDH1A1
SCHEMBL26033832 0.72 CLK1 (0.35) KDM4EHSD17B10TSHRGLAALDH1A1
SCHEMBL24685167 0.71 BAZ2B (0.33) KDM4EHSD17B10TSHRGLAALDH1A1
SCHEMBL29192347 0.71 BAZ2B (0.33) KDM4EHSD17B10TSHRGLAALDH1A1
SCHEMBL24685173 0.71 BAZ2B (0.33) KDM4EHSD17B10TSHRGLAALDH1A1
SCHEMBL24685553 0.71 HPGD (0.44) KDM4EHSD17B10TSHRGLAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313981-B1 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS PFIZER (US) 2026-02-25 — — EP disclosed
US-20250263411-A1 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS PFIZER INC. (US) 2025-08-21 — — US disclosed
CN-117561255-A 3, 4-dihydro-2, 7-naphthyridine-1, 6 (2H, 7H) -dione compounds as MEK inhibitors 辉瑞公司 2024-02-13 — — CN disclosed
EP-4313981-A1 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS Pfizer Inc. (US) 2024-02-07 — — EP disclosed
US-20240002384-A1 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS PFIZER INC. (US) 2024-01-04 — — US disclosed
US-11802127-B2 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors PFIZER INC. (US) 2023-10-31 — — US disclosed
US-11802127-B2 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors PFIZER INC. (US) 2023-10-31 — — US disclosed
US-11802127-B2 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors PFIZER INC. (US) 2023-10-31 — — US disclosed
US-11691973-B2 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors PFIZER INC. (US) 2023-07-04 — — US disclosed
US-11691973-B2 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors PFIZER INC. (US) 2023-07-04 — — US disclosed
US-11691973-B2 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors PFIZER INC. (US) 2023-07-04 — — US disclosed
US-20230120188-A1 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS PFIZER INC. (US) 2023-04-20 — — US disclosed
US-20220324861-A1 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS PFIZER INC. (US) 2022-10-13 — — US disclosed
WO-2022208391-A1 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS PFIZER INC, (US) 2022-10-06 — — WO disclosed
WO-2022208391-A1 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS PFIZER INC, (US) 2022-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324861-A1 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS NRAS, KRAS, MAPK1 KDM4E 302/4885HSD17B10 1478/4885TSHR 2583/4885
US-20230120188-A1 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS NRAS, KRAS, MAPK1 KDM4E 302/4885HSD17B10 1478/4885TSHR 2583/4885
US-11691973-B2 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors NRAS, KRAS, MAPK1 KDM4E 302/4885HSD17B10 1478/4885TSHR 2583/4885
US-20240002384-A1 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS NRAS, KRAS, BRAF KDM4E 330/4885HSD17B10 1940/4885TSHR 3778/4885
US-20250263411-A1 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS NRAS, KRAS, BRAF KDM4E 330/4885HSD17B10 1940/4885TSHR 3778/4885
US-11802127-B2 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors NRAS, KRAS, MAPK1 KDM4E 302/4885HSD17B10 1478/4885TSHR 2583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.